G. V. Dzyak

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

Shaun G. Goodman, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

The ODYSSEY OUTCOMES trial, comprising over 47 000 patient-years of placebo-controlled observation, demonstrated important reductions in the risk of recurrent ischaemic cardiovascular events with the monoclonal antibody to proprotein convertase subtilisin/kexin type 9 alirocumab, as well as lower all-cause death. These benefits …

ca, fr, us, ar, nl, nz, de (code pays fourni par la source)

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

BACKGROUND: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain. METHODS: The ODYSSEY OUTCOMES trial …

se, ru, fr, gb, us, ar, ca, nl, gr, de, nz (code pays fourni par la source)

Кардиоренальный синдром: патофизиология, верификация, подходы к лечению

G. V. Dzyak, Paul A. Kaplan

No abstract

Effects of blood pressure and lipid lowering on cognition

Jackie Bosch, Martin O’Donnell, Balakumar Swaminathan, Eva Lonn et autres

OBJECTIVE: To assess whether long-term treatment with candesartan/hydrochlorothiazide, rosuvastatin, or their combination can slow cognitive decline in older people at intermediate cardiovascular risk. METHODS: The Heart Outcomes Prevention Evaluation-3 (HOPE-3) study was a double-blind, randomized, placebo-controlled clinical trial using a 2 × …

ca (code pays fourni par la source)

[THE EXPERTS CONSENSUS FOR ANTICOAGULANT THERAPY OF VENOUS THROMBOEMBOLISM IN 2016 YR. SIGNIFICANCE OF THE RIVAROXABAN INVESTIGATIONS PROGRAM FOR CHANGES OF APPROACHES, CONCERNING TREATMENT OF THE DEEP VEINS THROMBOSIS AND PULMONARY THROMBOEMBOLISM].

S V Burnayeva, I I Vasilyeva, V K Gavrisyuk, С. И. Герасименко et autres

[PP.03.12] PULSE WAVE VELOCITY CHANGES IN PATIENTS WITH ESSENTIAL HYPERTENSION AND DIFFERENT CATEGORY OF CARDIOVACULAR RISK

Ewald Kolesnik, G. V. Dzyak, T. Kolesnik, K. Iegorov et autres

Objective: Research objective was studying of the PWV features at male patients with essential hypertension (EH) stage I-II and moderate and severe cardiovascular risk. Design and method: It were surveyed 128 male patients with EH of 1–3 degrees. All patients were divided …

ua (code pays fourni par la source)

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

Sean D. Pokorney, Jonathan P. Piccini, Susanna R. Stevens, Manesh R. Patel et autres

BACKGROUND: Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. METHODS AND RESULTS: In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for …

us, de, au, gb (code pays fourni par la source)

Diastolic function of the left ventricular in athletes with small abnormalities of heart development.

G. V. Dzyak

The purpose of our research was studying of cardiovascular system overexertion symptoms by dynamic of diastolic function of left ventricle during exercises of different power in athletes with small abnormalities of heart development. Wesurveyed 70 athletesaged 12-27 years.Thediastolicfunctiondynamicsof leftventricularisshowedinthework. Themainindexesofmyocardiumrelaxationdisorders duringdiastolearedefined.Itisprovedthatinathleteswithsmall abnormalities …

Structural and functional condition of the left ventricle and the arterial wall stiffness in patients with essential hypertension

G. V. Dzyak, E. L. Kolesnik

Impact of the left ventricular hypertrophy (LVH) and increasing of the pulse wave velocity in aorta (PWV) at cardiovascular risk proved in various groups of patients.Aim. The aim of the study was to investigate the features of the myocardial structural and functional …

Structural and functional condition of the left ventricle and the arterial wall stiffness in patients with essential hypertension

G. V. Dzyak, E. L. Kolesnik

и ИММЛЖ/р 2,7 за счёт увеличения толщины межжелудочковой перегородки. У больных ГБ с уже сформированной ГЛЖ на процесс ремоделирования сердца существенно влияет повышение центрального систолического и центрального пульсового артериального давления (ЦПАД). У больных с ГБ и ГЛЖ повышение ЦПАД способствует увеличению размера …

Myocardial Deformation and Rotation in Hypertensive Men With Different Degrees of Left Ventricular Hypertrophy

G. V. Dzyak, M.Y. Kolesnyk Kolesnyk

Pitavastatin – a new inhibitor of the HMG-CoA reductase: peculiarities of clinical pharmacology and perspectives of its usage in treatment of cardiovascular diseases.

G. V. Dzyak, K. Yu. Yegorov, E. L. Kolesnik

Cardiovascular mortality makes up 66.3 % of the total mortality in Ukraine. Myocardial infarction, stroke, atherosclerosis of peripheral arteries are the diseases caused by atherosclerosis and are prevalent in the mortality structure. One of the most effective means of successful prevention of …

ua (code pays fourni par la source)